Amylyx Pharmaceuticals, Inc. AMLX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $90.4M-13.1% | $104.08M-18.8% | $128.19M+37.2% | $93.45M+112% | ||
| $62.89M-45.0% | $114.33M-39.3% | $188.36M+48.2% | $127.13M— | ||
| $153.29M-61.9% | $402.1M+17.6% | $341.98M+53.0% | $223.57M— | ||
| -$153.29M+51.3% | -$314.73M-911% | $38.8M+119% | -$201.34M-143% | ||
| $9.3M-32.6% | $13.81M-14.5% | $16.16M+276% | $4.29M+11,819% | ||
| $8.6M-31.7% | $12.6M-18.7% | $15.5M+314% | $3.74M+171% | ||
| -$144.69M+52.1% | -$302.14M-656% | $54.3M+127% | -$197.6M-125% | ||
| $46K+112% | -$393K-108% | $5.03M+549% | $774K— | ||
| -$144.74M+52.0% | -$301.74M-712% | $49.27M+125% | -$198.38M-126% | ||
| -$1.53+65.5% | -$4.43-733% | $0.70+121% | -$3.40+74.5% | ||
| -$1.53+65.5% | -$4.43-707% | $0.73+121% | -$3.40+74.5% | ||
| 362.7M+33.3% | 272.1M-3.1% | 280.7M+23.7% | 226.9M+772% | ||
| 362.7M+33.3% | 272.1M+1.3% | 268.6M+18.4% | 226.9M— | ||
| —— | —— | —— | -$551K-980% | ||
| -$153.29M+51.3% | -$314.73M-911% | $38.8M+119% | -$201.34M-143% | ||
| -$152.77M+51.3% | -$313.83M-887% | $39.89M+120% | -$200.85M-143% | ||
| -$152.77M+51.3% | -$313.83M-887% | $39.89M+120% | -$200.85M-143% | ||
| -$153.29M+51.3% | -$314.73M-911% | $38.8M+119% | -$201.34M-143% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 100.0% and operating margin is -47349.8%, with a -45096.2% net margin.
- Where does Amylyx Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.